clarithromycin has been researched along with norfloxacin in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Gaillard, JL; Jackson, M; McDonnell, G; Niederweis, M; Skovierová, H; Svetlíková, Z | 1 |
| Hamasuna, R; Jensen, JS; Osada, Y | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Hakanen, AJ; Huovinen, P; Kotilainen, P; Lehtopolku, M; Nakari, UM; Siitonen, A | 1 |
| Mima, T; Schweizer, HP | 1 |
| Bohnert, JA; Karamian, B; Nikaido, H | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Frimpong, EK; Honda, T; Voravuthikunchai, SP; Yoh, M | 1 |
| Nakanishi, T; Nasu, T; Nishino, T; Okamoto, K | 1 |
| Katouno, Y; Kobayashi, Y; Sugita, K; Uchida, H | 1 |
| Bagnardi, V; Botteri, E; Carobbio, A; Corrao, G; Falcone, C; Leoni, O; Zambon, A | 1 |
| Abebe, W; Moges, F; Molla, R; Tiruneh, M | 1 |
1 review(s) available for clarithromycin and norfloxacin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
15 other study(ies) available for clarithromycin and norfloxacin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs.
Topics: Antitubercular Agents; Disinfectants; Drug Resistance, Bacterial; Glutaral; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Mycobacterium chelonae; Mycobacterium smegmatis; o-Phthalaldehyde; Porins | 2009 |
Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
Topics: Microbial Sensitivity Tests; Mycoplasma genitalium; Polymerase Chain Reaction | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
Topics: Anti-Bacterial Agents; Campylobacter coli; Campylobacter Infections; Campylobacter jejuni; Carbapenems; Drug Resistance, Multiple, Bacterial; Erythromycin; Feces; Finland; Humans; Macrolides; Microbial Sensitivity Tests; Minocycline; Tigecycline | 2010 |
The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Burkholderia pseudomallei; Culture Media; Drug Resistance, Multiple, Bacterial; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Mutation; Periplasmic Proteins; Quorum Sensing; Singapore; Virulence Factors | 2010 |
Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.
Topics: Anti-Bacterial Agents; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Chlortetracycline; Dipeptides; Doxorubicin; Doxycycline; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Proteins; Minocycline; Onium Compounds; Organophosphorus Compounds; Tetracycline | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Effect of subinhibitory concentrations of antimicrobial agents (quinolones and macrolide) on the production of verotoxin by enterohemorrhagic Escherichia coli O157:H7.
Topics: Animals; Anti-Infective Agents; Azithromycin; Bacterial Toxins; Chlorocebus aethiops; Clarithromycin; Dose-Response Relationship, Drug; Enterotoxins; Erythromycin; Escherichia coli O157; Fluoroquinolones; Humans; Macrolides; Norfloxacin; Piperazines; Quinolones; Shiga Toxin 1; Time Factors; Vero Cells | 1999 |
[In vitro antibacterial activity of faropenem, a novel oral penem antibiotic, against enterohemorrhagic Escherichia coli O157 strains].
Topics: Amoxicillin; Ampicillin; Anti-Bacterial Agents; Bacterial Toxins; beta-Lactams; Cefdinir; Cephalosporins; Clarithromycin; Escherichia coli O157; Fosfomycin; Kanamycin; Lactams; Microbial Sensitivity Tests; Minocycline; Norfloxacin; Shiga Toxin 1 | 1999 |
[Comparative in vitro activities of several antimicrobial agents against Helicobacter pylori].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ciprofloxacin; Clarithromycin; Drug Resistance, Bacterial; Erythromycin; Fluoroquinolones; Gastric Mucosa; Helicobacter pylori; Humans; Levofloxacin; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Penicillins; Stomach Ulcer | 2002 |
Generating signals of drug-adverse effects from prescription databases and application to the risk of arrhythmia associated with antibacterials.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Bacterial Agents; Arrhythmias, Cardiac; Case-Control Studies; Ciprofloxacin; Clarithromycin; Cohort Studies; Community Health Planning; Databases, Factual; Drug Monitoring; Erythromycin; Humans; Italy; Levofloxacin; Miocamycin; Norfloxacin; Ofloxacin; Pharmacoepidemiology; Risk Factors | 2005 |
Bacterial profile and antimicrobial susceptibility patterns in chronic suppurative otitis media at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Chronic Disease; Ciprofloxacin; Clarithromycin; Ethiopia; Hospitals, Special; Hospitals, University; Humans; Microbial Sensitivity Tests; Norfloxacin; Otitis Media, Suppurative; Proteus mirabilis; Staphylococcus aureus | 2019 |